News and reflections from the world of AI

    February 15, 2022

    Aiforia signs agreement with South Korean biotech company to augment its novel drug discovery platform with AI

    The two companies announced an agreement to add Aiforia’s artificial intelligence technology to Genuv’s ATRIVIEW® proprietary drug discovery platform, used to screen both existing drugs and new substances for neuroprotective and neuroregenerative effects. ATRIVIEW® was used to discover Genuv’s leading drug candidate, SNR1611, which has shown the ability to restore CNS function in preclinical ...
    Written by Aiforia
    January 17, 2022

    Aiforia appoints VP of Sales, Americas

    Aiforia, a software company providing pathologists with AI-based solutions for clinical diagnostics and preclinical analysis, today announced that Marco Comianos has joined the company as VP of Sales, Americas. Comianos will oversee sales efforts, as well as driving new business, revenue growth, and more partnerships with top hospitals and pharma companies across the region.
    Written by Aiforia
    January 12, 2022

    Aiforia launches a collaboration with Mayo Clinic to transform pathology practice with AI-powered solutions

    Aiforia, a technology company providing deep learning AI software for image analysis in pathology, and Mayo Clinic announced today that they are collaborating to establish an AI-powered pathology research support architecture at the Mayo Clinic. Leveraging each other’s expertise in digital pathology and deep learning, the two aim to enable faster results and scalable studies in translational ...
    Written by Aiforia
    December 20, 2021

    End of year message from the CEO

    Hi everyone,
    Written by Aiforia
    November 16, 2021

    Aiforia achieves CE-IVD mark for clinical PD-L1 AI model in lung cancer diagnostics

    Worldwide the most common cause of cancer mortality in 2020 was lung cancer, with an estimated 1.80 million deaths occurring¹. Fortunately immunotherapies are increasing in prominence and efficacy². A popular target for these novel therapeutics is PD-L1, a vital biomarker indicating cancer progression³. The calculation of PD-L1 presence in tumors is routinely used in clinical pathology as a ...
    Written by Aiforia
    September 23, 2021

    Aiforia Earns ISO 27001 Security Certification

    Aiforia has received ISO 27001 certification, the premier global standard for Information Security Management Systems. With this certification, Aiforia highlights its mission to maintain the highest standards for information security in its AI-assisted digital pathology products.
    Written by Aiforia
    1 2 3 4 5